trending Market Intelligence /marketintelligence/en/news-insights/trending/scaIjUR8waqicQGM7UBYbg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Catalyst to raise $46.6M from common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Catalyst to raise $46.6M from common stock offering

Catalyst Pharmaceuticals Inc. priced its public offering of 14,285,715 common shares at $3.50 apiece for expected net proceeds of about $46.6 million.

The company has also granted the underwriters an overallotment option to buy up to an additional 2,142,857 shares.

Catalyst plans to use the proceeds to fund clinical studies and precommercialization activities of its MuSK-antibody positive myasthenia gravis and spinal muscular atrophy treatment Firdapse and for general corporate purposes.

The offering is expected to close Nov. 30.

Piper Jaffray & Co. is acting as the lead book runner. SunTrust Robinson Humphrey Inc. is also acting as a book runner. H.C. Wainwright & Co. is acting as lead manager and Roth Capital Partners is acting as co-manager for the offering.